Related Experiment Video
Updated: May 6, 2026
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Surface Engineered Osteoblast-Extracellular Vesicles Serve as an Efficient Carrier for Drug and Small RNA to Actively
Sasmita Samal1,2, Gyanendra Prasad Panda1, Sharmishtha Shyamal1,3
1BRIC - Institute of Life Sciences (BRIC-ILS), Bhubaneswar 751023, Odisha, India.
Abstract:
Osteosarcoma (OS) is a rare malignant tumor that affects soft tissue and has high rates of lung metastasis and mortality. The primary treatments for OS include preoperative chemotherapy, surgical resection of the lesion, and postoperative chemotherapy. However, OS chemotherapy presents critical challenges related to treatment toxicity and multiple drug resistance. To address these challenges, nanotechnology has developed nanosystems that release drugs directly to OS cells, reducing the drug's toxicity. Extracellular vesicles (EVs) are nanosized lipid-bilayer bound vesicles that act as cell-derived vehicles and drug delivery systems for several cancers. This study aims to utilize EVs for OS management by co-delivering Hdac1 siRNA and zoledronic acid (zol). The EVs' surface is modified with folic acid (FA) and their targeting ability is compared to that of native EVs. The results showed that the EVs' targeting ability depends on the parent cell source, and FA conjugation further enhanced it. Furthermore, EVs were used as the carrier for co-loading drug (zol) and small RNA (Hdac-1). This approach of using surface engineered EVs as carriers for cargo loading and delivery can be a promising strategy for osteosarcoma management.
Insights
This study explores using engineered extracellular vesicles (EVs) to deliver chemotherapy drugs and gene silencing agents directly to osteosarcoma (OS) cells, overcoming drug resistance and reducing toxicity for better cancer management.
Area of Science:
- Nanotechnology
- Oncology
- Biochemistry
Background:
- Osteosarcoma (OS) is a rare bone cancer with high metastasis and mortality rates.
- Current OS treatments face challenges with drug toxicity and multidrug resistance.
- Nanotechnology offers potential solutions for targeted drug delivery to OS cells.
Purpose of the Study:
- To investigate the use of extracellular vesicles (EVs) for co-delivering Hdac1 siRNA and zoledronic acid (zol) for osteosarcoma management.
- To evaluate the enhanced targeting ability of EVs modified with folic acid (FA).
Main Methods:
- Engineered EVs were developed to co-load Hdac1 siRNA and zoledronic acid.
- EVs were modified with folic acid (FA) to enhance targeting.
- The targeting efficiency of native EVs and FA-conjugated EVs was compared based on parent cell source.
Main Results:
- EVs derived from specific parent cells exhibited distinct targeting abilities.
- Folic acid (FA) conjugation significantly enhanced the targeting capability of EVs.
- Surface-engineered EVs successfully co-loaded and delivered both zoledronic acid and Hdac1 siRNA.
Conclusions:
- Surface-modified EVs represent a promising strategy for targeted drug and gene silencing agent delivery in osteosarcoma.
- This approach offers a potential method to overcome chemotherapy resistance and reduce systemic toxicity in OS treatment.
